07:00 , Apr 2, 2007 |  BC Week In Review  |  Clinical News

Ceprotin regulatory update

FDA approved Ceprotin human protein C concentrate to treat severe congenital protein C deficiency. The human protein C product, which has Orphan Drug status in the U.S., was approved in Europe in 2001 (see BioCentury,...
01:09 , Mar 31, 2007 |  BC Extra  |  Company News

FDA approves Ceprotin

FDA approved Ceprotin human protein C concentrate from Baxter (BAX) to treat severe congenital protein C deficiency. The product has Orphan Drug status in the U.S. and was approved in Europe in 2001....
07:00 , Jul 23, 2001 |  BC Week In Review  |  Clinical News

Ceprotin human protein C regulatory update

The EMEA granted marketing approval for Ceprotin to treat blood clotting complications related to congenital protein C deficiency. Baxter Healthcare Corp. (BAX), Deerfield, Ill.   Product: Ceprotin human protein C   Business: Hematology  ...